näNO biomed has an innovative sustained-release drug-delivery system that was developed at Albert Einstein College of Medicine by Joel Friedman MD PhD and Adam Friedman MD FAAD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods™, to deliver—in a sustained-and controlled manner, for 24+ hours—notoriously hard-to-deliver therapeutic agents through topical administration.
Notably, the Nanopod™ delivery system has harnessed the therapeutic potential of Nitric Oxide (NO), one of the most notable and versatile yet elusive biomolecules produced by practically every cell in our bodies for enumerable biological activities, and curcumin (diferuloylmethane), a natural polyphenol with an extensive body of mechanistic and clinical data, but plagued by poor bioavailability (and by the persistent yellow stain it leaves behind). The topically applied Nanopods™ address these and many limitations of both established and emerging active ingredients.

The Nanopod™ delivery system is a breakthrough technology and holds promise for the treatment of a variety of skin and soft tissue infections, chronic wounds, inflammatory diseases of the skin such as Acne Vulgaris, osteoarthritis, and erectile dysfunction. Over 30 scientific peer-reviewed papers have been published demonstrating the efficacy and safety of several Nanopod™ encapsulated platforms including NO-releasing, curcumin-releasing , siRNA-releasing, and amphotericine-releasing Nanopods™ in a multitude of animal models.

NITRIC OXIDE: For the past three decades, nitric oxide (NO) has occupied the vanguard of free radical biology investigation due to its remarkable physiological versatility. Regulation of the vasculature, broad spectrum antimicrobial activity, wound healing, skin cell maturation and survival are all hallmarks of NO’s diverse functionality. NO’s role in medicine, especially its dermatological relevance and potential as a therapeutic is scientifically demonstrated. Unfortunately, exploitation of NO’s robust arsenal as a therapeutic presents many hurdles due to its small size, abrupt half-life and instability…until now.
Human proof-of-concept: Nitric Oxide has demonstrated human proof-of-concept in the following indications: (i) for the treatment of term and late pre-term (>34 weeks) neonates with pulmonary hypertension (“blue baby syndrome”) in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (FDA approved); (ii) in patients with genital warts caused by Human Papillomavirus, or HPV, in a Phase 2 study; (iii) for nail fungus in a Phase 2b study, and (iv) for acne vulgaris in a Phase 2b acne study.

CURCUMIN: Curcumin, or diferuloylmethane, is a crystalline compound that gives the Asian spice turmeric its bright yellow color. The medicinal qualities of turmeric/curcumin have been established for thousands of years and references to this spice have been seen in numerous cultures throughout the world. Today, there is growing scientific evidence suggesting curcumin’s utility (i) for the treatment of chronic pain, skin infections, viral warts, and inflammatory conditions such as psoriasis, (ii) for acceleration of wound closure, and (iii) for cosmetic ailments such as dyspigmentation. Curcumin exerts its activity through a number of different pathways in the body and is currently being investigated for therapeutic uses in various disease states ranging from cancer to autoimmune or inflammatory disorders. In addition, numerous studies have elucidated the protective effects of curcumin against various pollutants and cytotoxic agents, which also indicates that curcumin may be beneficial in a mitigational or prophylaxis role. Interestingly, curcumin provides an ideal alternative to other drugs because of its relative safety profile, even at high doses.
Although the advantageous properties of curcumin in medicine are well established, its therapeutic potential thus far has been limited because of its poor bioavailablity. A topical administration of curcumin could be highly beneficial because it would be directly delivered to the affected tissue making it useful in treating skin-related disorders. However, limitations still exist for a topical preparation such as the cosmetically unpleasing bright yellow-orange color of the compound, its poor absorption through the skin, and its poor stability at a higher pH…..until now.

CANNABINOIDS Cannabinoids are currently used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, and to treat chronic pain and muscle spasms. Cannabinoids are also currently in various stages of clinical trials to treat epilepsy, sclerosis, lupus, schizophrenia, and a variety of other disorders. A sustained-release topical mode of application has significant potential to help treat these disorders, and many others as well. Due to the regulatory environment and to the specialized nature of the various derivatized forms of cannabinoids, näNO will likely out-license the development of cannabinoid-related product candidates.